SYRS

Insider Trades

Name	Value	Action	Price	Current Price
Simonian Nancy ADirector $10k37.1k shares SellDec 2, 2024 $0.2702 $0.0002
Simonian Nancy ADirector $36k134.7k shares SellNov 25, 2024 $0.2653 $0.0002
Roth DavidChief Medical Officer $2.4k12.1k shares SellNov 18, 2024 $0.1969 $0.0002
Haas JasonChief Financial Officer $29k137.8k shares SellNov 18, 2024 $0.2103 $0.0002
Chee ConleyDirector, Officer: President & CEO $27k134.8k shares SellNov 18, 2024 $0.1998 $0.0002
Quirk Gerald EChief Legal & Compliance Offic $10k46.7k shares SellNov 19, 2024 $0.2212 $0.0002

News

defenseworld.netCritical Analysis: Syros Pharmaceuticals (NASDAQ:SYRS) & ADVANZ PHARMA (OTCMKTS:CXRXF)defenseworld.netApr 2

defenseworld.netCyclacel Pharmaceuticals (NASDAQ:BGMS) vs. Syros Pharmaceuticals (NASDAQ:SYRS) Head to Head Analysisdefenseworld.netMar 11

Trade SYRS

About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.

CEO: James E. Bradner
IPO Date: Jun 30, 2016

Market Data

Open: $0.0001
High: $0.0001
Low: $0.0001
Volume: 904
52W High: $0.04
52W Low: $0.0001

Valuation

Market Cap: $2.7K
Enterprise Value: -$77.4M

Financials

Free Cash Flow: -$110M
Revenue: $9.9M
Net Income: -$164.6M
Cash: $139.5M
Debt: $62.1M

Events

EarningsJul 29